Novartis Institutes for Biomedical Research and Genomics Institute of the Novartis Research Foundation to treat melanoma with a specific mutation in B-RAF kinase V600E, selective mutant B-RAF kinase inhibitor
LGX818 is currently in Phase Ib/II clinical trials. Patients with colon cancer or melanoma with the BRAF mutation, including patients resistant to other BRAF-targeted drugs, are receiving LGX818 pills alone or as part of drug cocktails to determine whether the drug is safe and efficacious
A phase Ib/II drug structure by Novartis disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat melanoma with a V600E mutation in the B-RAF kinase which it inhibits.
Several clinical trials of LGX818 , either alone or in combinations with the MEK inhibitorMEK162, CDK4 inhibitor LEE011 are being run. The initial results are encouraging .
- C. Drahl, Liveblogging First-Time Disclosures of Drug Structures from #ACSNOLA, 2013, http://cenblog.org/the-haystack/2013/04/liveblogging-first-time-disclosures-of-drug-structures-from-acsnola/